Day 2 recordPCAC favorable

Peptide dossier / July 23–24, 2026

Epitalon

The official record contained circadian and melatonin-related signals, but no direct insomnia trial using the nominated SC product and no clinical safety record.

Read the verdict Hear the testimony

free base7–4–1Yes · No · Abstain · n=12Recorded at 04:54:31.680 acetate7–4–1Yes · No · Abstain · n=12Recorded at 05:01:31.680

Decision boundaryPCAC advice is not FDA approval, does not establish safety or effectiveness, and did not itself place either form on the 503A Bulks List.

Editorial review

The central tension in this record.

FDA staff recommended against both forms; PCAC voted favorably on both form-level questions.

Evidence signal01

The circadian hypothesis is testable

FDA reviewed melatonin-related and telomerase-related findings. Those signals explain scientific interest and can generate hypotheses.

FDA briefing pp. 29, 33–35

Decisive limitation02

Mechanism did not become an insomnia outcome

The record lacked direct behavioral or EEG sleep evidence, an SC insomnia trial, pharmacokinetic data and a clinical safety dataset.

FDA briefing pp. 29–40

PeptideBase read

The committee outcome belongs beside the evidence record—not on top of it. A favorable advisory vote describes the panel’s recommendation on compounding eligibility; it does not erase FDA’s characterization, route-match or human-evidence concerns.

The case made in the room

Named speakers. Their strongest argument. Then the record check.

These are attributed testimony arguments, not PeptideBase endorsements. Each one is paired with the most relevant FDA answer and an explicit assessment of what the evidence can—and cannot—carry.

2named speaker moments

100%recording checked

Only named, source-reconciled speaker moments that were checked against the recording appear here. Statements remain attributed arguments unless the underlying evidence was independently established; no machine-caption wording is published as a quotation.

01Supports listing

Alex Tatem, MD

Board-certified urologist; fellowship-trained in male fertility, microsurgery and sexual medicine

Verify credentials

Attributed testimony

The circadian-mechanism case

Tatem described a proposed pathway connecting Epitalon with melatonin production and circadian regulation, then cited historical work as supporting context. A mechanistic account is not the same as a controlled insomnia result.

epitalon session · attributed argument, not an established factAudio-checked paraphrasePlay the source03:55:02–03:55:45

02Opposes listing

Peter Lurie, MD, MPH

President and Executive Director, Center for Science in the Public Interest; former FDA Associate Commissioner

Verify credentials

Attributed testimony

The hearing-wide case against all seven

Lurie said CSPI opposed adding all seven substances. He argued that the FDA criteria had not been met, that compounded products could create consumer risks, and that listing could weaken incentives for development through the standard drug-approval pathway.

Opening public hearing · explicitly applied to all seven substancesAudio-checked paraphrasePlay the source00:57:09–00:57:55

Claim-specific check

A proposed melatonin and circadian mechanism supports an insomnia rationale for Epitalon.

Mechanistic and historical

What supports it

The testimony described cell-level and historical findings. A plausible mechanism does not show that the nominated subcutaneous product improves insomnia in patients.

FDA’s answer

FDA found no identified study in patients with insomnia via the proposed subcutaneous route and raised immunogenicity and continuous-exposure carcinogenicity concerns.

FDA Day 2 presentation · 04:26:12

PeptideBase assessment

The circadian hypothesis is coherent enough to test. It is not a clinical insomnia result and does not answer route-specific or long-term safety questions.

Why the judgments diverged

Historical lineage and mechanism did not satisfy FDA’s use-specific test.

The favorable majority appears to have given weight to historical use, circadian biology and the prospect of regulated production. FDA centered its analysis on insomnia via the proposed subcutaneous route and found the clinical and safety record insufficient.

Editorial inference from the hearing record—not an attributed rationale for every voter

Claim versus record

What the official material supports—and what it does not.

These are recurring propositions in the wider peptide discussion, not attributed speaker quotations.

Sleep mechanism

Recurring claim

Melatonin findings establish that Epitalon treats insomnia.

Official record

FDA described melatonin-related findings but said the relevant monkey study did not assess sleep behavior or electroencephalographic sleep endpoints and that no nonclinical sleep-endpoint study was identified.

What it does not establish

A biomarker or mechanistic signal does not establish a clinically meaningful insomnia outcome.

FDA briefing pp. 29, 34

Long-term safety

Recurring claim

Telomerase activity establishes anti-aging benefit without a cancer concern.

Official record

FDA discussed telomerase and telomere-length findings and raised a potential carcinogenicity concern for chronic continuous exposure.

What it does not establish

The available intermittent-dose animal studies were too limited to resolve long-term risk; the concern is mechanistic and unresolved, not proof that Epitalon causes cancer.

FDA briefing pp. 33–35, 39–41

Evidence architecture

Eight questions applied consistently.

“Absent” means FDA said it did not identify that evidence within this evaluation. It is not a universal claim that no evidence exists anywhere.

Evidence questions applied to Epitalon, with FDA’s record summary and a locator.
Evidence question	Status	FDA-record summary	Locator
Human clinical evidence	absent	FDA identified no study in patients with insomnia using the proposed SC route.	Briefing pp. 29–32
Nonclinical evidence	indirect	Melatonin and circadian signals were identified without behavioral or EEG sleep endpoints.	Briefing pp. 29, 34
Exact-form match	contested	Nominations were inconsistent about free base versus acetate, and related substances were not interchangeable.	Briefing pp. 7–16
Nominated-route match	absent	The nominated SC route lacked direct insomnia effectiveness and human safety data.	Briefing pp. 29–32, 37–40
Evaluated-use match	absent	FDA found no direct evidence supporting insomnia treatment with the nominated product.	Briefing pp. 29–32
Product characterization	limited	FDA considered both forms not well characterized.	Briefing pp. 8–21
Human safety	absent	FDA said it identified no clinical safety data for Epitalon-related substances in humans.	Briefing pp. 35–40
Historical compounding use	limited	FDA found the extent of historical compounding use unclear.	Briefing pp. 21–25

Qualitative evidence map · no numerical score · scoped to FDA’s July 2026 evaluation

FDA findings

Five parts of the staff case.

01characterizationBoth epitalon free base and epitalon acetate were considered not well characterized.Day 2 pp. 81, 84
04:19:26 02effectivenessFDA found a lack of evidence supporting effectiveness for insomnia, including no identified study in patients with insomnia via the proposed subcutaneous route.Day 2 p. 91
04:26:12 03safetyFDA found no clinical safety data and raised concerns about potential immunogenicity and continuous-exposure carcinogenic risk.Day 2 pp. 92–98
04:28:04 04historical useFDA found the extent of historical use in compounding unclear.Day 2 pp. 99–102
04:32:24 05recommendationFDA proposed that neither epitalon free base nor epitalon acetate be included on the 503A Bulks List.Day 2 pp. 102–103
04:33:30

What changes the assessment

Open evidence gaps and direct sources.

A useful dossier should show the reader what evidence could materially strengthen or weaken the current read.

A controlled insomnia trial using the exact form and SC route

Clinical pharmacokinetic, immunogenicity and safety evidence

Long-term carcinogenicity and finished-product quality characterization